NASDAQ:VRTX

Vertex Pharmaceuticals Stock News

etoro logo Buy VRTX
*Your capital is at risk
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Vertex has a lock on the market for cystic fibrosis (CF) medicines. Now, it's also commercializing a promising, new gene therapy.
Alphabet could extend its momentum with a strong economy and the launch of a powerful new AI model. D.R. Horton stands to benefit from potential interest rate cuts in 2024.
Vertex Pharmaceuticals will pay Editas Medicine to license its Cas-9 gene-editing technology. Editas can still license the same technology to other companies.
Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.
The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but tha
Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in b

Is Vertex Pharmaceuticals Sitting on a Gold Mine?

05:00am, Thursday, 21'st Dec 2023
Vertex's cystic fibrosis treatments have generated blockbuster revenue over time -- and growth continues. The company now is wrapping up a pivotal program meant to address one of the most common healt
On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflati
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. Mor
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
These stocks are set to benefit from artificial intelligence and gene editing, two game-changing technologies. Companies investing in these technologies today could see their earnings take off over ti

Wells Fargo's top pharma picks for 2024

05:33pm, Friday, 15'th Dec 2023
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE